Skip to main content
Top
Published in: BMC Nephrology 1/2019

Open Access 01-12-2019 | Glomerulonephritis | Case report

Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis

Authors: Lin-Lin Li, Zhi-Ying Li, Su-Xia Wang, Xiao-Juan Yu, Ying Tan, Yu Wang, Feng Yu, Ming-Hui Zhao

Published in: BMC Nephrology | Issue 1/2019

Login to get access

Abstract

Background

C3 glomerulonephritis (C3GN) is a rare disease caused by inherited or acquired complement alternative pathway (CAP) dysregulation, which could also be secondary to monoclonal gammopathy of undetermined significance (MGUS). Herein, we described a patient presenting with C3GN and monoclonal gammopathy, and the pathogenic association between the two diseases was further explored in vitro.

Case presentation

A 76-year-old Chinese man presented with low serum C3 level, haematuria and nephrotic syndrome, and experienced rapid worsening of renal function over a period of 10 months. His serum and urine immunofixation electrophoresis both revealed a monoclonal IgGλ. A bone marrow puncture showed plasma cell dyscrasias with the highest plasma cell count of 5.25%. Kidney biopsy showed the presence of C3 glomerulonephritis, with exclusive deposits of C3 visible on immunofluorescence, a membranoproliferative pattern on light microscopy and electron dense deposits in sub-epithelial, intramembranous, sub-endothelial and mesangial regions by electron microscopy. The patient was positive for C3 nephritic factor (C3NeF) activity and anti-CFH autoantibodies, and all became negative during disease remission. The anti-CFH autoantibodies purified from the patient’s plasma exchange fluids were proven to be a monoclonal IgGλ, and could inhibit CFH binding to C3b and accelerate the formation of C3 convertase indirectly by interfering with the formation-impeding activity of CFH. No deficiency of candidate genes, especially variants in CFH, was detected in our patient. Based on the pathological and laboratory findings, the diagnosis of monoclonal gammopathy of renal significance (MGRS)-associated C3GN was finally made.

Conclusions

This is the first demonstration that intact monoclonal immunoglobulin (IgGλ) could act as an anti-CFH antibody and lead to MGRS-associated C3GN by activating the CAP.
Literature
1.
go back to reference Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010;6(8):494–9.CrossRef Fakhouri F, Fremeaux-Bacchi V, Noel LH, Cook HT, Pickering MC. C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010;6(8):494–9.CrossRef
2.
go back to reference Pickering MC, D'agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–89.CrossRef Pickering MC, D'agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84(6):1079–89.CrossRef
3.
go back to reference Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol. 2012;7(2):265–74.CrossRef Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol. 2012;7(2):265–74.CrossRef
4.
go back to reference Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–64.CrossRef Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–64.CrossRef
5.
go back to reference Lloyd IE, Gallan A, Huston HK, Raphael KL, Miller DV, Revelo MP, et al. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin Kidney J. 2016;9(6):794–9.CrossRef Lloyd IE, Gallan A, Huston HK, Raphael KL, Miller DV, Revelo MP, et al. C3 glomerulopathy in adults: a distinct patient subset showing frequent association with monoclonal gammopathy and poor renal outcome. Clin Kidney J. 2016;9(6):794–9.CrossRef
6.
go back to reference Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711.CrossRef Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698–711.CrossRef
7.
go back to reference Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal Gammopathy research group. Nat Rev Nephrol. 2019;15(1):45–59.CrossRef Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal Gammopathy research group. Nat Rev Nephrol. 2019;15(1):45–59.CrossRef
8.
go back to reference Bridoux F, Desport E, Fremeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9):2165–74.CrossRef Bridoux F, Desport E, Fremeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol. 2011;6(9):2165–74.CrossRef
9.
go back to reference Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977–82.CrossRef Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56(5):977–82.CrossRef
10.
go back to reference Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013;62(3):506–14.CrossRef Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis. 2013;62(3):506–14.CrossRef
11.
go back to reference Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: ten Years' experience at Mayo Clinic. Mayo Clin Proc. 2018;93(8):991–1008.CrossRef Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: ten Years' experience at Mayo Clinic. Mayo Clin Proc. 2018;93(8):991–1008.CrossRef
12.
go back to reference Chauvet S, Fremeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017;129(11):1437–47.CrossRef Chauvet S, Fremeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, et al. Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood. 2017;129(11):1437–47.CrossRef
13.
go back to reference Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, et al. Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal Gammopathy associated-C3 Glomerulopathy. Front Immunol. 2018;9:2260.CrossRef Chauvet S, Roumenina LT, Aucouturier P, Marinozzi MC, Dragon-Durey MA, Karras A, et al. Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal Gammopathy associated-C3 Glomerulopathy. Front Immunol. 2018;9:2260.CrossRef
14.
go back to reference Daccueil F, Masani NN, D'agati VD, Shirazian S. A 61-year-old man with Membranoproliferative glomerulonephritis. Am J Kidney Dis. 2017;70(6):A16–20.CrossRef Daccueil F, Masani NN, D'agati VD, Shirazian S. A 61-year-old man with Membranoproliferative glomerulonephritis. Am J Kidney Dis. 2017;70(6):A16–20.CrossRef
15.
go back to reference Timmermans S, Van Paassen P, Limburg RR. Conservative treatment for C3 glomerulopathy and monoclonal Ig. Kidney Int. 2018;94(3):632.CrossRef Timmermans S, Van Paassen P, Limburg RR. Conservative treatment for C3 glomerulopathy and monoclonal Ig. Kidney Int. 2018;94(3):632.CrossRef
16.
go back to reference Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94(1):178–86.CrossRef Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int. 2018;94(1):178–86.CrossRef
17.
go back to reference Yin G, Cheng Z, Zeng CH, Liu ZH. C3 glomerulonephritis in multiple myeloma: a case report and literature review. Medicine (Baltimore). 2016;95(37):e4843.CrossRef Yin G, Cheng Z, Zeng CH, Liu ZH. C3 glomerulonephritis in multiple myeloma: a case report and literature review. Medicine (Baltimore). 2016;95(37):e4843.CrossRef
18.
go back to reference Kyle Ra TT, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal Gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.CrossRef Kyle Ra TT, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal Gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9.CrossRef
19.
go back to reference Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175(4):939–50.CrossRef Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med. 1992;175(4):939–50.CrossRef
20.
go back to reference Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163(8):4590–6. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol. 1999;163(8):4590–6.
21.
go back to reference Hamzi MA, Zniber A, Badaoui GE, Mahtat E, Alhamany Z, Bayahia R, et al. C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. Indian J Nephrol. 2017;27(2):141–4.CrossRef Hamzi MA, Zniber A, Badaoui GE, Mahtat E, Alhamany Z, Bayahia R, et al. C3 glomerulopathy associated to multiple myeloma successfully treated by autologous stem cell transplant. Indian J Nephrol. 2017;27(2):141–4.CrossRef
22.
go back to reference Hirashio S, Satoh A, Arima T, Mandai K, Awaya T, Oshima K, et al. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report. BMC Nephrol. 2018;19(1):108.CrossRef Hirashio S, Satoh A, Arima T, Mandai K, Awaya T, Oshima K, et al. Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report. BMC Nephrol. 2018;19(1):108.CrossRef
23.
go back to reference Ramirez GA, De Luca G, Dell'antonio G, Baldissera E, Suma GV, Tresoldi M, et al. C3-glomerulopathy and MGUS: the skin beyond the kidney. QJM. 2018;111(3):187–8.CrossRef Ramirez GA, De Luca G, Dell'antonio G, Baldissera E, Suma GV, Tresoldi M, et al. C3-glomerulopathy and MGUS: the skin beyond the kidney. QJM. 2018;111(3):187–8.CrossRef
24.
go back to reference Lepori N, Cheungpasitporn W, Sethi S, Murray D, Kumar S, Leung N, et al. High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. Clin Nephrol. 2018;89(4):291–9.CrossRef Lepori N, Cheungpasitporn W, Sethi S, Murray D, Kumar S, Leung N, et al. High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. Clin Nephrol. 2018;89(4):291–9.CrossRef
25.
go back to reference Moog P, Jost PJ, Buttner-Herold M. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. BMC Nephrol. 2018;19(1):106.CrossRef Moog P, Jost PJ, Buttner-Herold M. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. BMC Nephrol. 2018;19(1):106.CrossRef
26.
go back to reference Gestur Vidarsson GD, Rispens T. IgG subclasses and allotypes- from structure to effector functions. Front Immunol. 2014;5:520. Gestur Vidarsson GD, Rispens T. IgG subclasses and allotypes- from structure to effector functions. Front Immunol. 2014;5:520.
27.
go back to reference Roux Kh SL, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997;159(7):3372–82.PubMed Roux Kh SL, Michaelsen TE. Flexibility of human IgG subclasses. J Immunol. 1997;159(7):3372–82.PubMed
28.
go back to reference Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, De Cordoba SR, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 2012;82(10):1084–92.CrossRef Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, De Cordoba SR, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 2012;82(10):1084–92.CrossRef
29.
go back to reference Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, et al. Unraveling the molecular mechanisms underlying complement Dysregulation by nephritic factors in C3G and IC-MPGN. Front Immunol. 2018;9:2329. Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, et al. Unraveling the molecular mechanisms underlying complement Dysregulation by nephritic factors in C3G and IC-MPGN. Front Immunol. 2018;9:2329.
30.
go back to reference Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc. 2013;88(11):1284–93.CrossRef Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc. 2013;88(11):1284–93.CrossRef
Metadata
Title
Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis
Authors
Lin-Lin Li
Zhi-Ying Li
Su-Xia Wang
Xiao-Juan Yu
Ying Tan
Yu Wang
Feng Yu
Ming-Hui Zhao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2019
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-019-1640-3

Other articles of this Issue 1/2019

BMC Nephrology 1/2019 Go to the issue